MiniMed Group Inc. Common Stock vs Regeneron Pharmaceuticals Inc — how do they compare? MiniMed Group Inc. Common Stock trades at $19.57 (market cap $5.38B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 14.2× MiniMed Group Inc. Common Stock's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while MiniMed Group Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold MiniMed Group Inc. Common Stock for 0 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| MMED | REGN | |
|---|---|---|
Market Cap | $5.38B | $76.40B |
Volume | 9,619,294 | 626,381 |
Sector | Health | Health |
52-Week High | $23.84 | $852.03 |
52-Week Low | $10.80 | $557.73 |
Typical Hold Time | 0 Days | 107 Days |
Enterprise Value | $5.18B | $71.12B |
Dividend Yield | — | 0.51% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
MiniMed develops, manufactures, and markets diabetes-management technologies. Its products include insulin-delivery systems, continuous glucose monitors, smart insulin pens, and related software.
Read more on MMED →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →